Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits

Publication date: June 2012
Number of pages: 60
Pricing:

- Single user license: $3,500
- Site license: $7,000
- Global site license: $10,500

Report Description

Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits analyzes the overall Supply Chain Management (SCM) scenario and provides profiles of the leading participants in the pharmaceutical supply chain in the US. The report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The top three wholesalers in the US, AmerisourceBergen Corporation, Cardinal Health and McKesson Corporation, accounted for 86.7% of the overall US pharmaceutical market in 2011 and combined revenue of $295.2 billion. Various supply chain models are followed across the pharmaceutical industry, such as traditional wholesaler models, limited distribution models and direct distribution models.

Pharmaceutical companies are now focusing on supply chains as a value-adding process rather than viewing them as a money drain, which was the scenario in the past. Managing a supply chain is a complicated task, as there are a number of issues that can affect performance and disrupt product and information flow. Counterfeits have emerged as the greatest threat to the smooth functioning of the supply chain in the US.